Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.

Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee.

J Am Heart Assoc. 2014 May 28;3(3):e000844. doi: 10.1161/JAHA.114.000844.

2.

Factors associated with D-dimer levels in HIV-infected individuals.

Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group; ESPRIT Study Group; SILCAAT Scientific Committee.

PLoS One. 2014 Mar 13;9(3):e90978. doi: 10.1371/journal.pone.0090978. eCollection 2014.

3.

Achilles tendinopathy following Kaletra (lopinavir/ritonavir) use.

Cresswell FV, Tomlins J, Churchill DR, Walker-Bone K, Richardson D.

Int J STD AIDS. 2014 Oct;25(11):833-5. doi: 10.1177/0956462414523403. Epub 2014 Feb 10.

PMID:
24516081
4.

Acute kidney injury as a presentation of primary renal diffuse large B-cell lymphoma in HIV.

Hughes DJ, Fitzgerald N, Sran H, Konig M, Moore-Moffatt R, Webb A, Gilleece Y, Churchill DR.

Int J STD AIDS. 2014 Apr;25(5):380-2. doi: 10.1177/0956462413505084. Epub 2013 Sep 18.

PMID:
24047882
5.

Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.

Bjerk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM; INSIGHT SMART Study Group.

PLoS One. 2013;8(2):e56249. doi: 10.1371/journal.pone.0056249. Epub 2013 Feb 15.

6.

Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.

Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group.

J Infect Dis. 2009 Sep 15;200(6):973-83. doi: 10.1086/605447.

7.

Trimetrexate and folinic acid: a valuable salvage option for Pneumocystis jirovecii pneumonia.

Short CE, Gilleece YC, Fisher MJ, Churchill DR.

AIDS. 2009 Jun 19;23(10):1287-90. doi: 10.1097/QAD.0b013e32832d0792.

PMID:
19424049
8.

Interruption of antiretroviral therapy is associated with increased plasma cystatin C.

Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M; INSIGHT SMART Study Group.

AIDS. 2009 Jan 2;23(1):71-82. doi: 10.1097/QAD.0b013e32831cc129.

9.

Abacavir-induced hepatotoxicity: a report of two cases.

Soni S, Churchill DR, Gilleece Y.

AIDS. 2008 Nov 30;22(18):2557-8. doi: 10.1097/QAD.0b013e32831c8af4. No abstract available.

PMID:
19005287
10.

Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.

Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Hullsiek KH, Stephan C, Lundgren J; SMART Study Group.

AIDS. 2008 Nov 12;22(17):2279-89. doi: 10.1097/QAD.0b013e328311d16f.

11.

Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.

SMART Study Group, El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, Emery S, Lundgren JD, Phillips A, Neaton JD.

Ann Intern Med. 2008 Sep 2;149(5):289-99.

PMID:
18765698
12.

Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN.

J Infect Dis. 2008 Apr 15;197(8):1145-55. doi: 10.1086/529523.

PMID:
18476293
13.

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R.

J Infect Dis. 2008 Apr 15;197(8):1133-44. doi: 10.1086/586713.

PMID:
18476292
14.

Knowledge, attitudes and health outcomes in HIV-infected travellers to the USA.

Mahto M, Ponnusamy K, Schuhwerk M, Richens J, Lambert N, Wilkins E, Churchill DR, Miller RF, Behrens RH.

HIV Med. 2006 May;7(4):201-4. Erratum in: HIV Med. 2006 Jul;7(5):345.

15.

Transient clinical deterioration in HIV patients with Pneumocystis carinii pneumonia after starting highly active antiretroviral therapy: another case of immune restoration inflammatory syndrome.

Dean GL, Williams DI, Churchill DR, Fisher MJ.

Am J Respir Crit Care Med. 2002 Jun 15;165(12):1670; author reply 1670. No abstract available.

PMID:
12070070
16.

A phase I/II study of the safety and activity of a microsphere formulation of KNI-272 in patients with HIV-1 infection.

Churchill DR, Slade PM, Youle M, Gazzard BG, Weber JN.

J Antimicrob Chemother. 2001 Mar;47(3):353-5.

PMID:
11222570
17.

Comparative quantification of diverse serotypes of HIV-1 in plasma from a diverse population of patients.

Clarke JR, Galpin S, Braganza R, Ashraf A, Russell R, Churchill DR, Weber JN, McClure MO.

J Med Virol. 2000 Dec;62(4):445-9.

PMID:
11074472
18.

Cushing's syndrome and severe adrenal suppression in patients treated with ritonavir and inhaled nasal fluticasone.

Chen F, Kearney T, Robinson S, Daley-Yates PT, Waldron S, Churchill DR.

Sex Transm Infect. 1999 Aug;75(4):274. No abstract available.

PMID:
10615321
19.

The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients.

Churchill DR, Pym AS, Galpin S, Foxall R, Stainsby C, Clarke JR, Kaye S, Bloor S, Larder BA, Wills B, Sun E, Babiker AG, Back DJ, Weber JN.

AIDS Res Hum Retroviruses. 1999 Sep 1;15(13):1181-9.

PMID:
10480631
20.

Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-1 infection.

Churchill DR, Pym AS, Babiker AG, Back DJ, Weber JN.

Br J Clin Pharmacol. 1998 Nov;46(5):518-9. No abstract available.

Supplemental Content

Loading ...
Support Center